Analysis of a Welsh program offering live-attenuated shingles vaccines to people born after a certain date showed a 20 percent relative drop in dementia risk.

The inoculation, produced by the Butantan Institute in partnership with Austrian Valneva, had its registration approved this ...

Study in older adults found that individuals who received the shingles vaccine were 20% less likely to develop dementia than those who were unvaccinated.

It’s worth noting that this study focused on Zostavax, the older live-attenuated shingles vaccine, not the newer recombinant vaccine, Shingrix, which is now more widely used (and the vaccine ...

The shingles vaccine, typically administered to fend off a painful rash, might pack an unexpected benefit by delaying or even ...

A recent study found that people who received Zostavax, a older shingles vaccine, had a lower risk of developing dementia.

The strongest set of evidence to date indicates that people who had a shingles vaccine had significantly lower odds of developing dementia later in life.

The vaccine for varicella-zoster virus, commonly known as shingles, could do far more than just protecting people from a rash ...

The vaccine for varicella-zoster virus, commonly known as shingles, could do far more than just protecting people from a rash ...

It makes sense to include routine adult vaccinations to our list of preventative measures, not only for prevention of common ...